Today Cantor Fitzgerald Maintains a “Buy” Rating on Catalyst Pharma (NASDAQ:CPRX) and a $8.0000 Target Price

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Logo

Investors sentiment decreased to 1.57 in 2018 Q2. Its down 0.27, from 1.84 in 2018Q1. It worsened, as 15 investors sold Catalyst Pharmaceuticals, Inc. shares while 20 reduced holdings. 17 funds opened positions while 38 raised stakes. 52.40 million shares or 1.84% less from 53.38 million shares in 2018Q1 were reported.

Colorado-based Alps has invested 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Hbk Sorce Advisory reported 21,109 shares or 0.01% of all its holdings. Kennedy invested in 1.05M shares or 0.06% of the stock. Jbf Cap owns 508,600 shares for 0.24% of their portfolio. State Common Retirement Fund invested 0% of its portfolio in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Mangrove holds 0.34% or 1.68M shares. Deutsche Fincl Bank Ag holds 163,703 shares or 0% of its portfolio. Boothbay Fund Limited Com invested in 84,181 shares. Meeder Asset Inc reported 16,512 shares. Acadian Asset Management Llc has 152,638 shares. The California-based Wells Fargo Com Mn has invested 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Royal Bankshares Of Canada holds 0% or 165,226 shares in its portfolio. The New Jersey-based Prudential Financial has invested 0% in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX). Commercial Bank Of Montreal Can holds 0% or 5,685 shares in its portfolio. Northern Corp invested in 0% or 1.11 million shares.

Since June 1, 2018, it had 3 insider purchases, and 0 insider sales for $84,774 activity. Another trade for 20,000 shares valued at $68,200 was bought by DENKHAUS DONALD A.

Catalyst Pharma (NASDAQ:CPRX) Rating Reaffirmed

They currently have a $8.0000 target on Catalyst Pharma (NASDAQ:CPRX). The target price by Cantor Fitzgerald would suggest a potential upside of 215.58 % from the company’s current stock price. This has been released in a research report on Wednesday morning.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Ratings Coverage

Among 2 analysts covering Catalyst Pharmaceuticals (NASDAQ:CPRX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Catalyst Pharmaceuticals has $8 highest and $6 lowest target. $7’s average target is 176.13% above currents $2.535 stock price. Catalyst Pharmaceuticals had 3 analyst reports since July 13, 2018 according to SRatingsIntel. On Wednesday, November 28 the stock rating was maintained by Cantor Fitzgerald with “Buy”.

The stock decreased 8.48% or $0.235 during the last trading session, reaching $2.535. About 6.45 million shares traded or 300.74% up from the average. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has risen 24.62% since December 2, 2017 and is uptrending. It has outperformed by 9.00% the S&P500.

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases. The company has market cap of $260.44 million. The Company’s lead product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in second Phase III clinical trials for the treatment of patients with Lambert-Eaton Myasthenic syndrome; and is in small blinded clinical trial to treat Congenital Myasthenic syndromes, as well as is in Phase II/III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis. It currently has negative earnings. The firm also develops CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor that is in Phase Ib clinical trial for the treatment of epilepsy, infantile spams, and Tourette's disorder; and CPP-109 to treat Tourette's disorder.

More notable recent Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) news were published by: which released: “Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst’s Autoimmune Disorder Drug Approved – Benzinga” on November 29, 2018, also with their article: “Wall Street Pulls Back After Major Rally – Nasdaq” published on November 29, 2018, published: “38 Stocks Moving In Friday’s Mid-Day Session – Benzinga” on November 30, 2018. More interesting news about Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) were released by: and their article: “Catalyst Pharma: A Rare Orphan Drug Opportunity With Low Risk – Seeking Alpha” published on November 21, 2018 as well as‘s news article titled: “Catalyst Pharmaceuticals, Inc. (CPRX) CEO Pat McEnany on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: November 08, 2018.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.